Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Rocket Pharmaceuticals, Inc. - Common Stock (NQ:RCKT)

3.055 -0.085 (-2.71%)
Streaming Delayed Price Updated: 3:58 PM EDT, Jul 31, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Rocket Pharmaceuticals, Inc. - Common Stock

< Previous 1 2
...
6 7 8 9 10 11 12 13 Next >
Rocket Pharmaceuticals Announces Positive Updates from Phase 1 Clinical Trial of RP-A501 in Danon Disease
From Rocket Pharmaceuticals, Inc.
Via Business Wire
Rocket Pharmaceuticals to Host Webcast on Nov. 15 at 8:30 a.m. ET to Present Updated Danon Disease Clinical Data
From Rocket Pharmaceuticals, Inc.
Via Business Wire
Rocket Pharmaceuticals Announces Participation in Stifel 2021 Virtual Healthcare Conference
From Rocket Pharmaceuticals, Inc.
Via Business Wire
The Week Ahead In Biotech (Aug. 8-14): Jazz Pharma FDA Decision, Earnings Deluge and IPOs In The Spotlight
Biopharma stocks ended higher for the week ending Aug. 6, as the sector latched on to the optimism that was evident in the broader markets. Earnings continued to flow in,... 
Via Benzinga
Rocket Pharmaceuticals Announces Danon Disease Presentation at the American Heart Association (AHA) Scientific Sessions 2021
From Rocket Pharmaceuticals, Inc.
Via Business Wire
Rocket Pharmaceuticals Announces Presentations Highlighting Three Lentiviral Gene Therapies at the 63rd American Society of Hematology (ASH) Annual Meeting
From Rocket Pharmaceuticals, Inc.
Via Business Wire
Rocket Pharmaceuticals Reports Third Quarter 2021 Financial Results and Highlights Recent Progress
From Rocket Pharmaceuticals, Inc.
Via Business Wire
The Daily Biotech Pulse: Novavax Retreats Amid Vaccine Issues, LumiraDx COVID Test Approved In India, Sesen Shines On Positive Bladder Cancer Review
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Novavax Shares React to Reports Of Manufacturing Issues With Its COVID-19... 
Via Benzinga
Rocket Pharma Posts Interim Data From Immunodeficiency Disorder Gene Therapy Trial
Rocket Pharmaceuticals Inc (NASDAQ: RCKT) has announced interim data updates from seven patients from the RP-L201 Phase 1/2 trial for Leukocyte Adhesion Deficiency... 
Via Benzinga
Rocket Pharmaceuticals Announces Positive Clinical Data from RP-L201 Trial for the Treatment of LAD-I at the 28th Annual Congress of the European Society of Gene & Cell Therapy (ESGCT)
From Rocket Pharmaceuticals, Inc.
Via Business Wire
Rocket Pharmaceuticals Announces Presentations Highlighting Lentiviral Gene Therapies at the 28th Annual Congress of the European Society of Gene & Cell Therapy (ESGCT)
From Rocket Pharmaceuticals, Inc.
Via Business Wire
Rocket Pharmaceuticals to Present at the 2021 Cell & Gene Meeting on the Mesa
From Rocket Pharmaceuticals, Inc.
Via Business Wire
Rocket Pharmaceuticals to Participate in the Chardan Virtual 5th Annual Genetic Medicines Conference
From Rocket Pharmaceuticals, Inc.
Via Business Wire
Rocket Pharmaceuticals Presents Clinical Data from RP-A501 Trial in Danon Disease at the Heart Failure Society of America (HFSA) Annual Scientific Meeting 2021
From Rocket Pharmaceuticals, Inc.
Via Business Wire
Rocket Pharmaceuticals Announces Upcoming Danon Disease Presentation at the Heart Failure Society of America Annual Scientific Meeting 2021
From Rocket Pharmaceuticals, Inc.
Via Business Wire
Rocket Pharmaceuticals Appoints Isabel Carmona, J.D., as Chief Human Resources Officer
From Rocket Pharmaceuticals, Inc.
Via Business Wire
Rocket Pharmaceuticals Announces $26.4 Million Private Placement
From Rocket Pharmaceuticals, Inc.
Via Business Wire
FDA Lifts Clinical Hold On Rocket Pharma's X-Linked Inherited Disorder Trial
The 
Via Benzinga
Rocket Pharmaceuticals Announces FDA Lifts Clinical Hold on Danon Disease Trial of RP-A501
From Rocket Pharmaceuticals, Inc.
Via Business Wire
Rocket Pharmaceuticals Reports Second Quarter 2021 Financial Results and Highlights Recent Progress
From Rocket Pharmaceuticals, Inc.
Via Business Wire
Rocket Pharmaceuticals to Host Conference Call on Aug. 9 at 4:30 p.m. ET to Discuss Second Quarter Results and Recent Business Highlights
From Rocket Pharmaceuticals, Inc.
Via Business Wire
The Week Ahead In Biotech: Mediwound, Provention FDA Decisions, IPOs, Pending Clinical Readouts In Focus
Biotech stocks reversed course and closed the week ended June 25 higher, thanks to the positive broader market sentiment. Eli Lilly and Company (NYSE: LLY) stood out among big... 
Via Benzinga
Earnings Scheduled For August 9, 2021
Companies Reporting Before The Bell • Privia Health Group (NASDAQ:PRVA) is projected to report quarterly loss at $1.57 per share on revenue of $215.17 million. •... 
Via Benzinga
74 Biggest Movers From Yesterday
Gainers Bit Digital, Inc. (NASDAQ: BTBT) shares jumped 109.7% to close at $8.87 on Monday after the company announced it entered into a second strategic co-mining agreement with... 
Via Benzinga
Short Interest Report: AMC Entertainment Shorts Sound Retreat
This week, Bed Bath & Beyond short interest hit a three-month high and the AMC Entertainment short position was down sharply. 
Via Talk Markets
Rocket Pharmaceuticals Announces Positive Data From RP-L102, RP-L201 Gene Therapy Programs
Rocket Pharmaceuticals Inc (NASDAQ: RCKT) has announced positive data from its Fanconi Anemia (FA), Leukocyte Adhesion Deficiency-I (LAD-I), and Pyruvate... 
Via Benzinga
Rocket Pharmaceuticals Presents Positive Clinical Data from Fanconi Anemia, Leukocyte Adhesion Deficiency-I, and Pyruvate Kinase Deficiency Programs at 24th Annual Meeting of the American Society of Gene and Cell Therapy
From Rocket Pharmaceuticals, Inc.
Via Business Wire
Rocket Pharma Stock Drops After FDA Institutes Clinical Hold On RP-A501 Danon Disease Trial
Tucked in the Q1 earnings release, Rocket Pharmaceuticals Inc (NASDAQ: RCKT) has paused the RP-A501 Phase 1 trial to treat Danon Disease to address the FDA... 
Via Benzinga
45 Stocks Moving In Tuesday's Mid-Day Session
Gainers Sequential Brands Group, Inc. (NASDAQ: SQBG) surged 52.6% to $14.76 after dropping 11% on Monday. 3D Systems Corporation (NYSE: DDD) shares climbed 22.9% to $21.83 after... 
Via Benzinga
The Daily Biotech Pulse: Minerva, InflaRx Report Positive Data Readouts, Lucira COVID-19 Test Kit Available On Amazon, Decision Day For Heron
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 11) HOOKIPA Pharma Inc. (NASDAQ... 
Via Benzinga
< Previous 1 2
...
6 7 8 9 10 11 12 13 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.